"Within-Trial" Prognostic Score Adjustment Is Targeted Maximum Likelihood Estimation

“试验内”预后评分调整是目标最大似然估计

阅读:1

Abstract

Adjustment for "super" or "prognostic" composite covariates has become more popular in randomized trials recently. These prognostic covariates are often constructed from historical data obtained from previous clinical trials or registries by fitting a predictive model of the outcome on the raw covariates. A natural question that we have been asked by applied researchers is whether this can be done without the historical data: can the prognostic covariate be constructed or derived from the trial data itself, possibly using different folds of the data, before adjusting for it? Here we clarify that such "within-trial" prognostic adjustment is nothing more than a form of targeted maximum likelihood estimation (TMLE), a well-studied procedure that typically improves the power of trial analyses. We therefore argue that there is no reason to reinvent the wheel: within-trial prognostic score adjustment should be referred to as TMLE, without qualification.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。